Panel: CMC cost of goods: The red flag we can't ignore - How advanced therapies fic the economics before scale makes it worse

The cost equation is breaking :Are allogeneic therapies genuinely approaching a manufacturing inflection point and if so, what does that mean for the long-term viability of autologous models that still struggle to generate margin?

Rethinking how and where ATMPs are made: What Europe’s decentralised production models (including Spain and the Nordics) reveal about alternative paths to scalE and whether point-of-care, intermediary hubs, or hybrid models can materially change COGS.

Breaking from the herd on CMC: Where technology, process innovation and supply-chain redesign (starting materials, import/export, last-mile delivery) can actually reduce cost and which bets companies need to make now rather than waiting for ‘the next platform’.